Megen Wittling
@megen-w.bsky.social
MD/PhD candidate in the Paulos Lab
Check out our new research on developing a model for tumor infiltrating lymphocyte (TIL) therapy for cholangiocarcinoma (CCA) by the Lesinski and Paulos Labs!
@lesinskilab.bsky.social
@chrystalpaulos.bsky.social
academic.oup.com/jimmunol/adv...
@lesinskilab.bsky.social
@chrystalpaulos.bsky.social
academic.oup.com/jimmunol/adv...
Development of a murine tumor-infiltrating lymphocyte therapy model for cholangiocarcinoma
Abstract. Tumor-infiltrating lymphocyte (TIL) therapy is a promising approach, earning U.S. Food and Drug Administration approval in patients with anti–PD-
academic.oup.com
September 24, 2025 at 1:00 PM
Check out our new research on developing a model for tumor infiltrating lymphocyte (TIL) therapy for cholangiocarcinoma (CCA) by the Lesinski and Paulos Labs!
@lesinskilab.bsky.social
@chrystalpaulos.bsky.social
academic.oup.com/jimmunol/adv...
@lesinskilab.bsky.social
@chrystalpaulos.bsky.social
academic.oup.com/jimmunol/adv...
Reposted by Megen Wittling
New Journal for ImmunoTherapy of Cancer position article and guidelines: Constructing the cure: engineering the next wave of antibody and cellular immune therapies bit.ly/3HYCbrs
#JITC #ImmunoSky #MedSky
#JITC #ImmunoSky #MedSky
Constructing the cure: engineering the next wave of antibody and cellular immune therapies
Immuno-oncology has revolutionized cancer treatment by mobilizing the immune system to eliminate tumors. Although immune checkpoint inhibitors and T cell therapies have mediated durable responses in h...
bit.ly
September 4, 2025 at 4:16 PM
New Journal for ImmunoTherapy of Cancer position article and guidelines: Constructing the cure: engineering the next wave of antibody and cellular immune therapies bit.ly/3HYCbrs
#JITC #ImmunoSky #MedSky
#JITC #ImmunoSky #MedSky
Reposted by Megen Wittling
🧵1/ New in @Cancer_Cell: Our lab discovered that Th17 cells must team up with B cells to eliminate tumors, and prevent it from coming back.
🔗 Read: www.cell.com/cancer-cell/...
🧬This unexpected immune duo sparks tumor immunity.
🖼️Image: See schematic Th17/B cell antitumor action!
🔗 Read: www.cell.com/cancer-cell/...
🧬This unexpected immune duo sparks tumor immunity.
🖼️Image: See schematic Th17/B cell antitumor action!
Adoptively transferred Th17 cells cooperate with host B cells to achieve durable tumor immunity
Cole et al. report that adoptively transferred, tumor-specific Th17 cells engage host
B cells and drive B cell proliferation and differentiation. These Th17 cells require
B cells for sustained immunit...
www.cell.com
July 25, 2025 at 2:51 PM
🧵1/ New in @Cancer_Cell: Our lab discovered that Th17 cells must team up with B cells to eliminate tumors, and prevent it from coming back.
🔗 Read: www.cell.com/cancer-cell/...
🧬This unexpected immune duo sparks tumor immunity.
🖼️Image: See schematic Th17/B cell antitumor action!
🔗 Read: www.cell.com/cancer-cell/...
🧬This unexpected immune duo sparks tumor immunity.
🖼️Image: See schematic Th17/B cell antitumor action!
Reposted by Megen Wittling
Check out our new paper in Hepatology on how myeloid cells limit immunotherapy in preclinical cholangiocarcinoma models!
Disease site matters! @chrystalpaulos.bsky.social @megen-w.bsky.social @winshipcancer.emory.edu many others!
pubmed.ncbi.nlm.nih.gov/40590857/
Disease site matters! @chrystalpaulos.bsky.social @megen-w.bsky.social @winshipcancer.emory.edu many others!
pubmed.ncbi.nlm.nih.gov/40590857/
Tumor site influences efficacy of MEKi and immunotherapy combinations in pre-clinical model of cholangiocarcinoma - PubMed
These findings identify myeloid cells as key mediators of both immunotherapy resistance and toxicity in CCA, highlighting the critical importance of tumor site and use of physiologically relevant pre-...
pubmed.ncbi.nlm.nih.gov
July 3, 2025 at 1:06 PM
Check out our new paper in Hepatology on how myeloid cells limit immunotherapy in preclinical cholangiocarcinoma models!
Disease site matters! @chrystalpaulos.bsky.social @megen-w.bsky.social @winshipcancer.emory.edu many others!
pubmed.ncbi.nlm.nih.gov/40590857/
Disease site matters! @chrystalpaulos.bsky.social @megen-w.bsky.social @winshipcancer.emory.edu many others!
pubmed.ncbi.nlm.nih.gov/40590857/
Reposted by Megen Wittling
Our findings highlight the critical role of T cell trafficking to the lymph nodes in shaping neoantigen-specific antitumor responses and offers insight for improving adoptive cellular therapies www.biorxiv.org/content/10.1...
Neoantigens drive adoptively transferred CD8 T cells to long-lived effectors mediated by lymph node trafficking
Adoptive transfer of neoantigen-reactive T lymphocytes mediates potent responses against solid tumors in patients while often limiting toxicity to normal tissues; however, the mechanisms governing the...
www.biorxiv.org
April 25, 2025 at 12:15 AM
Our findings highlight the critical role of T cell trafficking to the lymph nodes in shaping neoantigen-specific antitumor responses and offers insight for improving adoptive cellular therapies www.biorxiv.org/content/10.1...
Reposted by Megen Wittling
Inspiring (as always) @cholangiocarcinoma.bsky.social annual meeting comes to a close. Our @winshipatemory.bsky.social team returns motivated by survivors, patients and caregivers to make a difference! @megen-w.bsky.social @chrystalpaulos.bsky.social
April 12, 2025 at 1:31 AM
Inspiring (as always) @cholangiocarcinoma.bsky.social annual meeting comes to a close. Our @winshipatemory.bsky.social team returns motivated by survivors, patients and caregivers to make a difference! @megen-w.bsky.social @chrystalpaulos.bsky.social
Reposted by Megen Wittling
💥Cheers to Megen Wittling @megen-w.bsky.social @winshipatemory.bsky.social for presenting exciting work on the distinct trafficking & activation patterns of adoptively transferred CD8 T cells that recognize non-mutated va mutated tumors.
March 27, 2025 at 1:42 AM
💥Cheers to Megen Wittling @megen-w.bsky.social @winshipatemory.bsky.social for presenting exciting work on the distinct trafficking & activation patterns of adoptively transferred CD8 T cells that recognize non-mutated va mutated tumors.
Reposted by Megen Wittling
Congrats to our talented grad student Megen Wittling for being award this NCI F30 grant for her work in adoptive immunotherapy today! @megen-w.bsky.social @winshipatemory.bsky.social @sitcancer.bsky.social #EmoryMSTP
February 19, 2025 at 2:31 PM
Congrats to our talented grad student Megen Wittling for being award this NCI F30 grant for her work in adoptive immunotherapy today! @megen-w.bsky.social @winshipatemory.bsky.social @sitcancer.bsky.social #EmoryMSTP
Reposted by Megen Wittling
🎉Congrats to Emory cancer immunologist Chrystal Paulos, PhD, (@chrystalpaulos.bsky.social) who has been named co-leader of the Cancer Immunology Research Program at Winship. ➡️ brnw.ch/21wQB3h
February 10, 2025 at 4:16 PM
🎉Congrats to Emory cancer immunologist Chrystal Paulos, PhD, (@chrystalpaulos.bsky.social) who has been named co-leader of the Cancer Immunology Research Program at Winship. ➡️ brnw.ch/21wQB3h
Reposted by Megen Wittling
Cheers to @megen-w.bsky.social and #HeatherLin in the CB program @winshipatemory.bsky.social for brilliant talks on adoptive immunotherapy in yesterdays seminar series.
January 28, 2025 at 1:04 PM
Cheers to @megen-w.bsky.social and #HeatherLin in the CB program @winshipatemory.bsky.social for brilliant talks on adoptive immunotherapy in yesterdays seminar series.